These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34396569)

  • 1. Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis.
    Okubo Y; Ohtsuki M; Komine M; Imafuku S; Kassir N; Petric R; Nemoto O
    J Dermatol; 2021 Nov; 48(11):1652-1664. PubMed ID: 34396569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    Ohtsuki M; Okubo Y; Komine M; Imafuku S; Day RM; Chen P; Petric R; Maroli A; Nemoto O
    J Dermatol; 2017 Aug; 44(8):873-884. PubMed ID: 28391657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
    Rich P; Gooderham M; Bachelez H; Goncalves J; Day RM; Chen R; Crowley J
    J Am Acad Dermatol; 2016 Jan; 74(1):134-42. PubMed ID: 26549249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial.
    Stein Gold L; Papp K; Pariser D; Green L; Bhatia N; Sofen H; Albrecht L; Gooderham M; Chen M; Paris M; Wang Y; Callis Duffin K
    J Am Acad Dermatol; 2022 Jan; 86(1):77-85. PubMed ID: 34343599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
    J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
    Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
    Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
    J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
    Paul C; Cather J; Gooderham M; Poulin Y; Mrowietz U; Ferrandiz C; Crowley J; Hu C; Stevens RM; Shah K; Day RM; Girolomoni G; Gottlieb AB
    Br J Dermatol; 2015 Dec; 173(6):1387-99. PubMed ID: 26357944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
    Paller AS; Hong Y; Becker EM; de Lucas R; Paris M; Zhang W; Zhang Z; Barcellona C; Maes P; Fiorillo L
    J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
    Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M
    J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials.
    Thaçi D; Kimball A; Foley P; Poulin Y; Levi E; Chen R; Feldman SR
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):498-506. PubMed ID: 27538241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
    Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
    J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial.
    Imafuku S; Nemoto O; Okubo Y; Komine M; Schafer P; Petric R; Ohtsuki M
    J Dermatol; 2021 Jan; 48(1):80-84. PubMed ID: 32909643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
    Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
    Strober B; Thaçi D; Sofen H; Kircik L; Gordon KB; Foley P; Rich P; Paul C; Bagel J; Colston E; Throup J; Kundu S; Sekaran C; Linaberry M; Banerjee S; Papp KA
    J Am Acad Dermatol; 2023 Jan; 88(1):40-51. PubMed ID: 36115523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
    Ighani A; Georgakopoulos JR; Zhou LL; Walsh S; Shear N; Yeung J
    J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.